Background:It may be impossible to perform cancer surgery with free margins in the presence of an unresectablestructure. Local drug treatment after surgery has been proposed to increase the rate of tumor control. Methods:Multi-nanolayers (10-330 nm) were generated by a low-pressure (375mTorr) inductively coupled plasma(13.56 MHz) reactor for anticancer drug delivery by the deposition of polycaprolactone-polyethylene glycolmultistack barrier on the collagen membrane (100μm thickness). Carboplatin (300μg/cm2) was used for the in vitroand in vivo investigations. Energy-dispersive X-ray spectroscopy (15 keV), scanning electron microscopy andinductively coupled plasma mass spectrometry were used to detect the presence of carboplatin in the nanolayer,the tumor sample and the culture medium. Preclinical studies were performed on ovarian (OVCAR-3NIH) and colon(CT26) cancer cell lines asxenografts (45 days)andallografts(23 days) in Swiss-nude (n= 6) and immunocompetentBALB/cByJ mice (n= 24), respectively. Results:The loading of carboplatin or other drugs between the nanofilm on the collagen membrane did notmodify the mesh complex architecture or the drug properties. Drugs were detectable on the membrane for morethan 2 weeks in the in vitro analysis and more than 10 days in the in vivo analysis. Cytotoxic mesh decreased celladherence (down 5.42-fold) and induced cancer cell destruction (up to 7.87-fold). Implantation of the mesh on themouse tumor nodule modified the cell architecture and decreased the tumor size (50.26%) compared to thecontrol by inducing cell apoptosis. Conclusion:Plasma technology allows a mesh to be built with multi-nanolayer anticancer drug delivery oncollagen membranes.